Profile data is unavailable for this security.
About the company
Bio-Path Holdings, Inc. is a biotechnology company. The Company is engaged in developing DNAbilize, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. DNAbilize, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body’s enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge. Its lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase II study for blood cancers, and BP1001-A, a drug product modification of prexigebersen, is in a Phase I/Ib study for solid tumors. The Company’s second product, BP1002, which targets the Bcl-2 protein, is being evaluated for the treatment of blood cancers and solid tumors, including lymphoma and acute myeloid leukemia. BP1003 is its third liposome delivered antisense drug candidate.
- Revenue in USD (TTM)0.00
- Net income in USD-11.60m
- Incorporated2014
- Employees10.00
- LocationBio Path Holdings Inc4710 BELLAIRE BOULEVARD, SUITE 210BELLAIRE 77401United StatesUSA
- Phone+1 (832) 742-1357
- Fax+1 (916) 443-1908
- Websitehttps://www.biopathholdings.com/